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Abstract: In order to compare the last version of the Respiratory Virus Panel (RVP) Fast assay for
human Adenovirus (hAdv) detection with a specific real-time polymerase chain reaction (qPCR),
which is considered the gold standard for hAdv detection, nasopharyngeal samples collected from
309 children (age range, four months to eight years) with respiratory tract infection were tested
using the RVP Fast v2 assay (Luminex Molecular Diagnostics, Inc., Toronto, ON, Canada) and a
specific TaqMan qPCR to identify hAdv DNA. The RVP Fast v2 assay detected 30/61 (49.2%) hAdv
infections that had been identified by real-time qPCR, demonstrating a significantly lower detection
rate (p < 0.001). The sensitivity of the RVP Fast v2 assay in comparison to qPCR was lower in
younger children (42.9% vs. 57.7%; Cohen’s kappa coefficient, 0.53); in samples with co-infections
(40.0% vs. 56.7%; Cohen’s kappa coefficient, 0.52); and in samples with hAdv type C
(45.9% vs. 57.1%; Cohen’s kappa coefficient, 0.60). Samples with lower viral loads were associated
with a significantly lower sensitivity of the RVP Fast v2 assay (35.1% vs. 68.2%, p = 0.01; Cohen’s kappa
coefficients, 0.49). The RVP Fast v2 assay has important limitations for the detection of hAdv and
cannot be used to evaluate whether hAdvs are the main etiologic agent responsible for an outbreak
or when epidemiological studies are performed.
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1. Introduction
Epidemics of different respiratory viruses simultaneously occur every winter season [1].
Unfortunately, the clinical symptoms are very similar regardless of the infectious agent, and only
laboratory assays can clearly identify the causative virus involved in each epidemic. The Luminex
Respiratory Virus Panel (RVP) Fast assay simultaneously detects 19 different viral and subtype targets
in respiratory secretions and has been demonstrated since the first version (RVP classic) to be a
more sensitive and less expensive method for viral detection compared to routine culture and direct
fluorescent assays (DFAs) [2]. Moreover, the RVP Fast assay is rapid and straightforward to perform
and can theoretically overcome some of the limitations of conventional real-time polymerase chain
reaction (qPCR) assays [3]. These points underscore why the RVP Fast assay is largely used instead
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of qPCR for the detection of multiple viral agents in clinical practice worldwide [1,4,5]. However,
direct comparisons of the RVP Fast assay with qPCR have shown that discordant results can occur
for some viruses, with reduced sensitivity of the RVP Fast assay observed mainly in samples with
low viral load [2,6]. This explains why the first RVP Fast Assay version was cleared by the Food and
Drug Administration for the detection of only eight viruses and subtypes and for application only to
nasopharyngeal swabs, leaving other specimens to be validated by the individual laboratories. The
second RVP Fast Assay version v2 includes two controls to ensure an increased assay performance,
but few data are available on its sensitivity and specificity in comparison to that of the qPCR assays
specifically prepared for the detection of each respiratory virus [2,7,8]. Using respiratory samples, this
study compared the sensitivity and specificity of the last version of the RVP Fast assay (the v2 version)
for human Adenovirus (hAdv) detection with those of qPCR, which is considered the gold standard.
2. Results
Table 1 summarizes the comparison between the RVP Fast v2 assay and qPCR assay for hAdv
detection. A total of 309 respiratory samples were evaluated, 140 of which were obtained from
children <3 years of age (age range, four to 35 months) and 169 of which were collected from
older subjects (age range, three to eight years). The RVP Fast v2 assay detected 30/61 (49.2%) of
hAdv infections that had been identified by qPCR, demonstrating a significantly lower detection rate
(p < 0.001). No case was identified that resulted in a positive RVP Fast v2 test and a negative qPCR
test. Overall, the sensitivity and specificity of the RVP Fast v2 assay compared with the results
of qPCR were 49.2% and 100%, respectively, with a positive predictive value (PPV) and negative
predictive value (NPV) of 100% and 88.9%, respectively. Concordance between the two methods of
hAdv identification was poor, as evidenced by the low Cohen’s kappa coefficient (0.61; 95% confidence
interval [CI]: 0.49–0.73). Viral loads were <106 cp/mL in 37/59 (62.7%) cases and ě106 log cp/mL
in 22/59 (37.3%) cases. Among the 61 samples, 30 did not show any evidence of co-infection, whereas
in the 30 additional samples, one or more viruses were detected alongside hAdv (in one sample
co-infection data were not available). Rhinovirus was the most common co-infecting agent (14 samples),
followed by RSV (10 samples), and influenza A (four samples). HAdv type was identified with
RT-PCR in 48/61 (78.7%) cases: seven (14.6%) as type B, 37 (77.1%) as type C and four (8.3%) as other
types (D, E or F).
Table 1. Comparison of the RVP Fast v2 assay and real-time PCR results for the detection of hAdv in
selected subgroups.
Adenovirus
RVP Fast v2 Assay
Negative Positive Total
Subjects <3 years old
Real-time PCR result
Negative 105 (75.0) 0 (0.0) 105 (75.0)
Positive 20 (14.3) 15 (10.7) 35 (25.0)
Total 125 (89.3) 15 (10.7) 140 (100.0)
Sensitivity 42.9% - -
Specificity 100% - -
PPV 100% - -
NPV 84.0% - -
Cohen’s kappa (95% CI) 0.53 (0.36–0.70) - -
Subjectsě3 years old
Real-time PCR result
Negative 143 (84.6) 0 (0.0) 143 (84.6)
Positive 11 (6.5) 15 (8.9) 26 (15.4)
Total 154 (91.1) 15 (8.9) 169 (100.0)
Sensitivity 57.7% - -
Specificity 100% - -
PPV 100% - -
NPV 92.9% - -
Cohen’s kappa (95% CI) 0.70 (0.53–0.86) - -
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Table 1. Cont.
Adenovirus
RVP Fast v2 Assay
Negative Positive Total
Negative or PCR viral load <106 cp/mL *
Real-time PCR result
Negative 248 (87.0) 0 (0.0) 248 (87.0)
Positive 24 (8.4) 13 (4.6) 37 (13.0)
Total 272 (95.4) 13 (4.6) 285 (100.0)
Sensitivity 35.1% - -
Specificity 100% - -
PPV 100% - -
NPV 91.2% - -
Cohen’s kappa (95% CI) 0.49 (0.32–0.65) - -
Negative or PCR viral loadě106 cp/mL *
Real-time PCR result
Negative 248 (91.8) 0 (0.0) 248 (91.8)
Positive 7 (2.6) 15 (5.6) 22 (8.2)
Total 255 (94.4) 15 (5.6) 270 (100.0)
Sensitivity 68.2% - -
Specificity 100% - -
PPV 100% - -
NPV 97.3% - -
Cohen’s kappa (95% CI) 0.80 (0.65–0.94) - -
Positivity to B subtype **
Real-time PCR result
Negative 248 (97.2) 0 (0.0) 248 (97.2)
Positive 3 (1.2) 4 (1.6) 7 (2.8)
Total 251 (98.4) 4 (1.6) 255 (100.0)
Sensitivity 57.1% - -
Specificity 100% - -
PPV 100% - -
NPV 98.8% - -
Cohen’s kappa (95% CI) 0.72 (0.42–1.00) - -
Positivity to C subtype ***
Real-time PCR result
Negative 248 (87.0) 0 (0.0) 248 (87.0)
Positive 20 (7.0) 17 (6.0) 37 (13.0)
Total 268 (94.0) 17 (6.0) 285 (100.0)
Sensitivity 45.9% - -
Specificity 100% - -
PPV 100% - -
NPV 92.5% - -
Cohen’s kappa (95% CI) 0.60 (0.44–0.75) - -
No co-infections detected §
Real-time PCR result
Negative 106 (77.9) 0 (0.0) 106 (77.9)
Positive 13 (9.6) 17 (12.5) 30 (22.1)
Total 119 (87.5) 17 (12.5) 136 (100.0)
Sensitivity 56.7% - -
Specificity 100% - -
PPV 100% - -
NPV 89.1% - -
Cohen’s kappa (95% CI) 0.67 (0.51–0.83) - -
Presence of co-infections §
Real-time PCR result
Negative 135 (81.8) 0 (0.0) 135 (81.8)
Positive 18 (10.9) 12 (7.3) 30 (18.2)
Total 153 (92.7) 12 (7.3) 165 (100.0)
Sensitivity 40.0% - -
Specificity 100% - -
PPV 100% - -
NPV 88.2% - -
Cohen’s kappa (95% CI) 0.52 (0.34–0.70) - -
* Viral loads were not available for two PCR-positive subjects; ** Excluding PCR-positive subjects with subtypes
other than “B”; *** Excluding PCR-positive subjects with subtypes other than “C”; § Information regarding
co-infection was not available for eight subjects; HAdv: human adenovirus; PPV: positive predictive value;
NPV: negative predictive value; real-time PCR: real-time polymerase chain reaction.
The sensitivity of the RVP Fast v2 assay in comparison with qPCR was lower in younger children
(42.9% vs. 57.7%), with a Cohen’s kappa coefficient of 0.53, compared with 0.70 in childreně3 years old
(p = 0.16 for comparison between kappa coefficients); in samples with co-infections (40.0% vs. 56.7%),
with a Cohen’s kappa coefficient of 0.52, compared with 0.67 in samples without co-infections (p = 0.23
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for comparison between kappa coefficients); and in samples with hAdv type C (45.9% vs. 57.1%), with
a Cohen’s kappa coefficient of 0.60, compared with 0.72 in hAdv type B infection. Samples with lower
viral loads were associated with a significantly lower sensitivity of the RVP Fast v2 assay (35.1% vs.
68.2%, p = 0.01), with a Cohen’s kappa coefficients of 0.49 for viral loads <106 cp/mL compared with
0.80 for viral loads ě106 cp/mL.
3. Discussion
HAdv plays a significant role in pediatric respiratory tract infections, accounting for 2%–5% of
overall respiratory illnesses and 4%–10% of community-acquired pneumonia [1,9]. Although most
cases are mild and indistinguishable from other viral agents, acute lower respiratory tract infections
(LRTIs) caused by hAdv can be severe or even fatal and are associated with a high risk of long-term
respiratory sequelae [10]. Thus, early identification of hAdv-caused severe respiratory infections
during outbreaks may be useful for monitoring the circulation of the virus and for planning the
development of adequate preventive and therapeutic measures. This study confirms that the RVP
Fast v2 assay still maintains the limitations observed when the first version of this laboratory test
was evaluated [2], suggesting that there remains a high risk that large numbers of hAdv-positive
respiratory samples will go unidentified if only this test is used for virus identification of respiratory
infections during epidemics.
The reasons for the poor sensitivity of the hAdv RVP Fast v2 assay are not precisely defined. In
this study, low viral loads were associated with a significantly lower detection rate than that observed
in samples with higher viral loads. This finding suggests that for hAdv, viral load is critical for the
efficient detection of positive samples using the RVP Fast v2 assay. However, this finding is in contrast
to the data reported by Gadsby et al. [3], who did not find any association between viral load and the
sensitivity of the previous version of the RVP Fast assay for hAdv detection. However, it is likely that
viral load is not the only factor contributing to the sensitivity and specificity of the RVP Fast v2 assay
for hAdv detection. In this study, additional samples with high viral loads that had tested positive for
hAdv by qPCR were not detected by the RVP Fast v2 assay. It has been suggested that suboptimal
primer binding to particular hAdv types could explain the poor sensitivity of the RVP Fast assays [4].
The primers have a mismatch with the adenovirus sequence, the amplicon has an extensive secondary
structure including primer and probe annealing sites, and there are extensive interactions within and
between primers. In this study, the sensitivity and specificity were found to be low for both hAdv
types B and C, suggesting that all hAdv types frequently involved in causing respiratory infections
could remain undetected by the RVP Fast v2 assay. However, suboptimal primer binding could still
be the underlying cause of these results, as the emergence of new hAdv types and recombinant and
intermediate strains occurs frequently [11], which could lead to variants that cannot be detected by
the RVP Fast v2 assay. Additionally, co-infections were associated with low sensitivity, indicating that
there was interference of other viruses in the detection rate of hAdv by the RVP Fast v2 assay.
4. Experimental Section
Nasopharyngeal samples collected from otherwise healthy children receiving treatment at the
Emergency Room of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy,
for respiratory tract infections in January 2014 were evaluated. The study was approved by the Ethics
Committee of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy. Written
informed consent of a parent or legal guardian was required, and children ě8 years of age were asked
to give their written assent. General characteristics of enrolled children were collected and archived on
a previously prepared electronic chart. Nasopharyngeal secretions were collected immediately after
admission to the Emergency Room using a paranasal flocked swab (one swab per child), which was
stored in a tube containing 1 mL of universal transport medium (Copan, Brescia, Italy).
Viral nucleic acids were extracted from the swab using the Nuclisens EasyMAG automated
extraction system (Biomeriéux, Craponne, France), and the extract was tested for respiratory viruses
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using the RVP Fast v2 assay (Luminex Molecular Diagnostics, Inc., Toronto, ON, Canada). This
assay simultaneously detects influenza A viruses (non-specific influenza A, A/H1N1, A/H3N2,
influenza A/H1N1 2009), influenza B virus, respiratory syncytial virus (RSV), parainfluenzaviruses
(types 1–4), hAdv, human metapneumovirus, coronaviruses (229E, NL63, OC43 and HKU1),
enterovirus/rhinovirus and human bocavirus, according to the manufacturer’s instructions (Luminex
Molecular Diagnostics Inc., Toronto, ON, Canada).
Viral nucleic acid extracts were also tested using a specific HAdV plasmid by a
single-plex qPCR using TaqMan Universal Master Mix II (Applied Biosystems, Foster City,
CA, USA). Amplification and detection of viral DNA was performed with a 7900HT
qPCR system instrument (Applied Biosystems). The real-time HAdV-specific primer
sequences were as follows: 5’-GCCACGGTGGGGTTTCTAAACTT-3’, Adenoquant 1 (AQ1) and
5’-GCCCCAGTGGTCTTACATGCACATC-3’, Adenoquant 2 (AQ2). The sequence of the probe was
5’-TGCACCAGACCCGGGCTCAGGTACTCCGA-3’ (Adenoprobe) labeled with FAM on the 5’-end
as a fluorescent dye and labeled with TAMRA on the 3’-end as a fluorescence quencher dye. Cycling
conditions were as follows: 50 ˝C for 2 min, 95 ˝C for 8 min and 50 cycles of 95 ˝C for 15 s and
59 ˝C for 1 min. The plasmid amplified target fragment was verified by sequencing. Plasmid
DNA concentrations were detected using an ND-1000 spectrophotometer (NanoDrop products,
Wilmington, DE, USA).
Positive results were also quantified with a HAdV-specific qPCR, as previously described [12].
QPCR was carried out in a total reaction volume of 20 µL consisting of 10 µL of TaqMan Universal
Master Mix (Applied Biosystems), 0.8 µL (0.4 mM) of each primer, 0.6 µL (0.3 mM) of the probe, 5 µL
of template, and 2.8 µL of double-distilled water. The qPCR thermal cycling reaction and quantitative
measurement were performed in a StepOne qPCR instrument (Applied Biosystems) using the following
conditions: one cycle at 50 ˝C for 2 min, one cycle at 95 ˝C for 10 min, 45 cycles at 95 ˝C for 15 s, and
one cycle at 60 ˝C for 1 min. Each run included plasmid and negative controls. Standard precautions
were taken throughout the PCR process to avoid cross-contamination. Negative controls and serial
dilutions of the plasmid positive control were included in every PCR assay. Finally, quantitative
results were reported as DNA copies/mL of respiratory samples. The limit of detection in this work
was 2.06 Log10. The samples were considered positive if the real-time PCR cycle threshold value
was ď42. Positive and negative controls were also included in each run.
The sensitivity, specificity, PPV, NPV, and Cohen’s kappa coefficients with 95% confidence
intervals (95% CI) of the kit were calculated; a kappa coefficient higher than 0.80 was considered to be
in agreement. The analyses were performed using SAS version 9.2 (Cary, NC, USA).
5. Conclusions
The RVP Fast v2 assay has important limitations for the detection of hAdv. This problems have
limited importance in everyday patient care because no specific therapy is presently available against
hAdvs. However, data collected with this study show that the RVP Fast v2 assay cannot be used
to evaluate whether hAdvs are the main etiologic agent responsible for an outbreak when several
respiratory viruses are simultaneously circulating or when epidemiological studies investigating the
incidence of different viral respiratory infections are performed.
Acknowledgments: This study was supported by a grant obtained from the Italian Ministry of Health (Bando
Giovani Ricercatori 2009 and Fondi Ricerca Corrente 2015 850/01).
Author Contributions: Susanna Esposito designed the study, supervised the patient enrollment and co-wrote
the manuscript; Alessia Scala and Alberto Zampiero performed the laboratory assays; Sonia Bianchini and
Emilio Fossali enrolled the patients; Nicola Principi performed the statistical analysis and co-wrote the manuscript.
All the authors approved the final version of the text.
Conflicts of Interest: None of the authors has any conflicts of interest to declare. The manufacturer of the RVP
Fast v2 assay did not participate in the study.
Int. J. Mol. Sci. 2016, 17, 297 6 of 6
References
1. Esposito, S.; Daleno, C.; Prunotto, G.; Scala, A.; Tagliabue, C.; Borzani, I.; Fossali, E.; Pelucchi, C.; Principi, N.
Impact of viral infections in children with community-acquired pneumonia: results of a study of 17
respiratory viruses. Influenza Other Respir. Viruses 2013, 7, 18–26. [CrossRef] [PubMed]
2. Mahony, J.; Chong, S.; Merante, F.; Yaghoubian, S.; Sinha, T.; Lisle, C.; Janeczko, R. Development of a
respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a
fluid microbead-based assay. J. Clin. Microbiol. 2007, 45, 2965–2970. [CrossRef] [PubMed]
3. Gadsby, N.J.; Hardie, A.; Claas, E.C.; Templeton, K.E. Comparison of the Luminex Respiratory Virus Panel
fast assay with in-house real-time PCR for respiratory viral infection diagnosis. J. Clin Microbiol. 2010, 48,
2213–2216. [CrossRef] [PubMed]
4. Lee, C.Y.; Chang, Y.F.; Lee, C.L.; Wu, M.C.; Ho, C.L.; Chang, Y.C.; Chan, Y.J. Molecular viral epidemiology and
clinical characterization of acute febrile respiratory infections in hospitalized children in Taiwan. J. Med. Virol.
2015, 87, 1860–1866. [CrossRef] [PubMed]
5. Zhu, R.; Song, Q.; Qian, Y.; Zhao, L.; Deng, J.; Wang, F.; Sun, Y. Virus profile in children with acute respiratory
infections with various severities in Beijing, China. Chin. Med. J. 2014, 127, 3706–3711. [PubMed]
6. Pabbaraju, K.; Wong, S.; Tokaryk, K.L.; Fonseca, K.; Drews, S.J. Comparison of the Luminex xTAG
respiratory viral panel with xTAG respiratory viral panel fast for diagnosis of respiratory virus infections.
J. Clin. Microbiol. 2011, 49, 1738–1744. [CrossRef] [PubMed]
7. Jokela, P.; Piiparinen, H.; Mannonen, L.; Auvinen, E.; Lappalainen, M. Performance of the Luminex xTAG
Respiratory Viral Panel Fast in a clinical laboratory setting. J. Virol. Methods 2012, 182, 82–86. [CrossRef]
[PubMed]
8. Choudhary, M.L.; Anand, S.P.; Tikhe, S.A.; Walimbe, A.M.; Potdar, V.A.; Chadha, M.S. Comparison of the
conventional multiplex RT-PCR, real time RT-PCR and Luminex xTAG® RVP fast assay for the detection of
respiratory viruses. J. Med. Virol. 2016, 88, 51–57. [CrossRef] [PubMed]
9. Jain, S.; Williams, D.J.; Arnold, S.R.; Ampofo, K.; Bramley, A.M.; Reed, C.; Stockmann, C.; Anderson, E.J.;
Grijalva, C.G.; Self, W.H.; et al. Community-acquired pneumonia requiring hospitalization among U.S.
children. N. Engl. J. Med. 2015, 372, 835–845. [CrossRef] [PubMed]
10. Edmond, K.; Scott, S.; Korczak, V.; Ward, C.; Sanderson, C.; Theodoratou, E.; Clark, A.; Griffiths, U.; Rudan, I.;
Campbell, H. Long term sequelae from childhood pneumonia; systematic review and meta-analysis.
PLoS ONE 2012, 7, e31239. [CrossRef] [PubMed]
11. Kaneko, H.; Aoki, K.; Ohno, S.; Ishiko, H.; Fujimoto, T.; Kikuchi, M.; Harada, S.; Gonzalez, G.; Koyanagi, K.O.;
Watanabe, H.; et al. Complete genome analysis of a novel intertypic recombinant human adenovirus causing
epidemic keratoconjunctivitis in Japan. J. Clin. Microbiol. 2011, 49, 484–490. [CrossRef] [PubMed]
12. Heim, A.; Ebnet, C.; Harste, G.; Pring-Akerblom, P. Rapid and quantitative detection of human adenovirus
DNA by real-time PCR. J. Med. Virol. 2003, 70, 228–239. [CrossRef] [PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons by Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
